DK3678687T3 - Mutant fgf-21 peptidkonjugater og anvendelser deraf - Google Patents
Mutant fgf-21 peptidkonjugater og anvendelser deraf Download PDFInfo
- Publication number
- DK3678687T3 DK3678687T3 DK18852510.9T DK18852510T DK3678687T3 DK 3678687 T3 DK3678687 T3 DK 3678687T3 DK 18852510 T DK18852510 T DK 18852510T DK 3678687 T3 DK3678687 T3 DK 3678687T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptide conjugates
- mutant fgf
- fgf
- mutant
- conjugates
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title 1
- 239000000863 peptide conjugate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553970P | 2017-09-04 | 2017-09-04 | |
| PCT/IB2018/001112 WO2019043457A2 (en) | 2017-09-04 | 2018-09-04 | CONJUGATES OF MUTANT PEPTIDE FGF-21 AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3678687T3 true DK3678687T3 (da) | 2022-11-14 |
Family
ID=65525090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18852510.9T DK3678687T3 (da) | 2017-09-04 | 2018-09-04 | Mutant fgf-21 peptidkonjugater og anvendelser deraf |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10407479B2 (da) |
| EP (1) | EP3678687B1 (da) |
| JP (1) | JP6852939B2 (da) |
| KR (1) | KR102229037B1 (da) |
| CN (2) | CN111225683B (da) |
| AU (1) | AU2018322943B2 (da) |
| CA (1) | CA3074380C (da) |
| DK (1) | DK3678687T3 (da) |
| ES (1) | ES2930534T3 (da) |
| IL (1) | IL272987B (da) |
| WO (1) | WO2019043457A2 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11427623B1 (en) | 2019-05-28 | 2022-08-30 | 89Bio Ltd. | Methods of treatment using mutant FGF-21 peptide conjugates |
| CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| US20230090114A1 (en) * | 2020-01-31 | 2023-03-23 | 89Bio Ltd. | Methods for promoting weight loss |
| US11596669B2 (en) | 2021-03-11 | 2023-03-07 | 89Bio, Inc. | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates |
| CN117120070A (zh) * | 2021-03-11 | 2023-11-24 | 89生物公司 | 包含突变型fgf-21肽peg化缀合物的液体制剂 |
| WO2023250493A1 (en) * | 2022-06-24 | 2023-12-28 | 89Bio Inc. | Compositions and methods of treatment for severe hypertriglyceridemia |
| WO2024044680A2 (en) * | 2022-08-24 | 2024-02-29 | 89Bio, Inc. | Methods of treatment of nash using mutant fgf-21 peptide conjugates |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922577A (en) | 1995-04-11 | 1999-07-13 | Cytel Corporation | Enzymatic synthesis of glycosidic linkages |
| US5876980A (en) | 1995-04-11 | 1999-03-02 | Cytel Corporation | Enzymatic synthesis of oligosaccharides |
| US5728554A (en) | 1995-04-11 | 1998-03-17 | Cytel Corporation | Enzymatic synthesis of glycosidic linkages |
| US6030815A (en) | 1995-04-11 | 2000-02-29 | Neose Technologies, Inc. | Enzymatic synthesis of oligosaccharides |
| US6127153A (en) | 1995-06-07 | 2000-10-03 | Neose Technologies, Inc. | Method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and gene encoding a polyglycosyltransferase |
| ES2218806T3 (es) | 1997-01-16 | 2004-11-16 | Neose Technologies, Inc. | Sialilacion practica in vitro de glicoproteinas recombinantes. |
| MXPA02011016A (es) | 2000-05-12 | 2004-03-16 | Neose Technologies Inc | Glicopeptidos recombinantes de glucolisacion in vitro. |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| SG177002A1 (en) | 2001-10-10 | 2012-01-30 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
| EP1461445B1 (en) | 2001-11-28 | 2008-08-20 | Neose Technologies, Inc. | Glycoprotein remodeling using endoglycanases |
| AU2002351197A1 (en) | 2001-11-28 | 2003-06-10 | Neose Technologies, Inc. | Glycopeptide remodeling using amidases |
| CA2485102A1 (en) | 2002-05-03 | 2003-11-13 | Neose Technologies, Inc. | Recombinant glycosyltransferase fusion proteins |
| EP1539989B1 (en) | 2002-07-23 | 2011-04-20 | BioGeneriX AG | Synthesis of oligosaccharides, glycolipids and glycoproteins using bacterial glycosyltransferases |
| US7344858B2 (en) | 2002-08-31 | 2008-03-18 | Cj Corp | Glycosylated human granulocyte colony-stimulating factor (G-CSF) isoform |
| CA2555109C (en) | 2004-02-04 | 2016-12-06 | Neose Technologies, Inc. | Methods of refolding mammalian glycosyltransferases |
| WO2005091944A2 (en) * | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
| EP1814573B1 (en) * | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| WO2008011633A2 (en) * | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| ATE554785T1 (de) | 2007-03-30 | 2012-05-15 | Ambrx Inc | Modifizierte fgf-21 polypeptide und ihre verwendung |
| EP2242505A4 (en) * | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
| CA2760674A1 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| ES2534936T3 (es) | 2010-08-02 | 2015-04-30 | Ratiopharm Gmbh | Método para producir y purificar una sialiltransferasa soluble activa |
| KR102077721B1 (ko) * | 2011-07-01 | 2020-02-14 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법 |
| PT3412302T (pt) * | 2014-10-24 | 2021-06-09 | Bristol Myers Squibb Co | Polipéptidos de fgf-21 modificados e utilizações dos mesmos |
| SI3236991T1 (sl) * | 2014-12-23 | 2019-09-30 | Novo Nordisk A/S | Derivati FGF21 in njihova uporaba |
| TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
-
2018
- 2018-09-04 DK DK18852510.9T patent/DK3678687T3/da active
- 2018-09-04 CN CN201880067272.XA patent/CN111225683B/zh active Active
- 2018-09-04 KR KR1020207009597A patent/KR102229037B1/ko active IP Right Grant
- 2018-09-04 EP EP18852510.9A patent/EP3678687B1/en active Active
- 2018-09-04 AU AU2018322943A patent/AU2018322943B2/en active Active
- 2018-09-04 ES ES18852510T patent/ES2930534T3/es active Active
- 2018-09-04 IL IL272987A patent/IL272987B/en unknown
- 2018-09-04 WO PCT/IB2018/001112 patent/WO2019043457A2/en unknown
- 2018-09-04 JP JP2020530492A patent/JP6852939B2/ja active Active
- 2018-09-04 CN CN202210261031.7A patent/CN114601932A/zh active Pending
- 2018-09-04 CA CA3074380A patent/CA3074380C/en active Active
- 2018-12-19 US US16/225,640 patent/US10407479B2/en active Active
-
2019
- 2019-07-18 US US16/515,544 patent/US20190389921A1/en not_active Abandoned
-
2021
- 2021-05-27 US US17/332,062 patent/US20210355183A1/en not_active Abandoned
-
2023
- 2023-05-31 US US18/326,510 patent/US20240116995A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210355183A1 (en) | 2021-11-18 |
| IL272987B (en) | 2022-08-01 |
| JP6852939B2 (ja) | 2021-03-31 |
| AU2018322943B2 (en) | 2020-06-04 |
| CA3074380C (en) | 2023-01-03 |
| US10407479B2 (en) | 2019-09-10 |
| IL272987A (en) | 2020-04-30 |
| ES2930534T3 (es) | 2022-12-16 |
| US20240116995A1 (en) | 2024-04-11 |
| KR102229037B1 (ko) | 2021-03-17 |
| CN111225683B (zh) | 2022-04-05 |
| JP2020532579A (ja) | 2020-11-12 |
| CN114601932A (zh) | 2022-06-10 |
| EP3678687A4 (en) | 2020-08-12 |
| EP3678687B1 (en) | 2022-08-17 |
| WO2019043457A3 (en) | 2019-07-25 |
| CN111225683A (zh) | 2020-06-02 |
| KR20200040307A (ko) | 2020-04-17 |
| CA3074380A1 (en) | 2019-03-07 |
| US20190389921A1 (en) | 2019-12-26 |
| EP3678687A2 (en) | 2020-07-15 |
| WO2019043457A2 (en) | 2019-03-07 |
| AU2018322943A1 (en) | 2020-04-16 |
| US20190185533A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3678687T3 (da) | Mutant fgf-21 peptidkonjugater og anvendelser deraf | |
| DK3849614T3 (da) | Interleukin-2-polypeptidkonjugater og anvendelser deraf | |
| DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
| DK3458479T3 (da) | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater | |
| DK3478811T3 (da) | Rengøringssammensætninger og anvendelser deraf | |
| DK3946464T3 (da) | Forbindelser og konjugater deraf | |
| DK3497094T3 (da) | Tlr7/8-antagonister og anvendelser deraf | |
| DK3412302T3 (da) | Modificerede fgf-21-polypeptider og anvendelser deraf | |
| DK3250237T3 (da) | Hemiasterlinderivater til konjugering og terapi | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3655401T3 (da) | Tlr7/8-antagonister og anvendelser deraf | |
| IL270595B1 (en) | Bi-octahydrophenanthrene carboxamides and their protein conjugates | |
| DK3641824T3 (da) | Hydrofile linkere og konjugater deraf | |
| IL265471A (en) | Pulling-oligonucleotide conjugates and their uses | |
| DK3334500T3 (da) | Multiligand-lægemiddelskonjugater og anvendelser deraf | |
| SG11202101517PA (en) | Isoquinoline-steroid conjugates and uses thereof | |
| IL275208A (en) | Hsp90-targeting conjugates and formulations thereof | |
| DK3638251T3 (da) | Bisphosphocin gel formuleringer og brug deraf | |
| IL282362A (en) | Intein proteins and their uses | |
| DK3525826T3 (da) | Ikke-lineære selvofrende linkere og konjugater deraf | |
| DK3743106T3 (da) | Influenzavirusvacciner og anvendelser deraf | |
| IL283942A (en) | Tubulysins and protein-tubulysin conjugation | |
| IL277791A (en) | HSP90 targeting conjugates and their formulations | |
| DK3544637T3 (da) | Native omv-antigenkonjugater og anvendelse deraf | |
| DK3590523T3 (da) | Vækstfremmende peptider og anvendelser deraf |